215 related articles for article (PubMed ID: 12682318)
1. Effect of L-dopa on plasma homocysteine in PD patients: relationship to B-vitamin status.
Miller JW; Selhub J; Nadeau MR; Thomas CA; Feldman RG; Wolf PA
Neurology; 2003 Apr; 60(7):1125-9. PubMed ID: 12682318
[TBL] [Abstract][Full Text] [Related]
2. Effect of L-dopa on plasma homocysteine in PD patients: relationship to B-vitamin status.
Schroecksnadel K; Leblhuber F; Fuchs D
Neurology; 2004 Feb; 62(4):676; author reply 676-7. PubMed ID: 14994447
[No Abstract] [Full Text] [Related]
3. Effect of L-dopa on plasma homocysteine in PD patients: relationship to B-vitamin status.
Di Rocco A; Werner P
Neurology; 2004 Feb; 62(4):676; author reply 676-7. PubMed ID: 14981202
[No Abstract] [Full Text] [Related]
4. Elevated plasma homocysteine levels in patients treated with levodopa: association with vascular disease.
Rogers JD; Sanchez-Saffon A; Frol AB; Diaz-Arrastia R
Arch Neurol; 2003 Jan; 60(1):59-64. PubMed ID: 12533089
[TBL] [Abstract][Full Text] [Related]
5. Hyperhomocysteinemia in L-dopa treated Parkinson's disease patients: effect of cobalamin and folate administration.
Lamberti P; Zoccolella S; Armenise E; Lamberti SV; Fraddosio A; de Mari M; Iliceto G; Livrea P
Eur J Neurol; 2005 May; 12(5):365-8. PubMed ID: 15804266
[TBL] [Abstract][Full Text] [Related]
6. Plasma homocysteine levels in Parkinson's disease: role of antiparkinsonian medications.
Zoccolella S; Lamberti P; Armenise E; de Mari M; Lamberti SV; Mastronardi R; Fraddosio A; Iliceto G; Livrea P
Parkinsonism Relat Disord; 2005 Mar; 11(2):131-3. PubMed ID: 15734674
[TBL] [Abstract][Full Text] [Related]
7. Elevated plasma homocysteine and low vitamin B-6 status in nonsupplementing older women with rheumatoid arthritis.
Woolf K; Manore MM
J Am Diet Assoc; 2008 Mar; 108(3):443-53; discussion 454. PubMed ID: 18313425
[TBL] [Abstract][Full Text] [Related]
8. Effect of MTHFR polymorphisms on hyperhomocysteinemia in levodopa-treated Parkinsonian patients.
Caccamo D; Gorgone G; Currò M; Parisi G; Di Iorio W; Menichetti C; Belcastro V; Parnetti L; Rossi A; Pisani F; Ientile R; Calabresi P
Neuromolecular Med; 2007; 9(3):249-54. PubMed ID: 17914182
[TBL] [Abstract][Full Text] [Related]
9. Higher plasma homocysteine is associated with lower vitamin B6 status in critically ill surgical patients.
Hou CT; Wu YH; Cheng CH; Huang PN; Huang YC
Nutr Clin Pract; 2012 Oct; 27(5):695-700. PubMed ID: 22868281
[TBL] [Abstract][Full Text] [Related]
10. Homocysteine in restless legs syndrome.
Bachmann CG; Guth N; Helmschmied K; Armstrong VW; Paulus W; Happe S
Sleep Med; 2008 May; 9(4):388-92. PubMed ID: 17900981
[TBL] [Abstract][Full Text] [Related]
11. Effects of vitamin B12, folate, and entacapone on homocysteine levels in levodopa-treated Parkinson's disease patients: A randomized controlled study.
Anamnart C; Kitjarak R
J Clin Neurosci; 2021 Jun; 88():226-231. PubMed ID: 33992189
[TBL] [Abstract][Full Text] [Related]
12. Reduced plasma homocysteine levels in levodopa/entacapone treated Parkinson patients.
Valkovic P; Benetin J; Blazícek P; Valkovicová L; Gmitterová K; Kukumberg P
Parkinsonism Relat Disord; 2005 Jun; 11(4):253-6. PubMed ID: 15878587
[TBL] [Abstract][Full Text] [Related]
13. Vitamins and entacapone in levodopa-induced hyperhomocysteinemia: a randomized controlled study.
Postuma RB; Espay AJ; Zadikoff C; Suchowersky O; Martin WR; Lafontaine AL; Ranawaya R; Camicioli R; Lang AE
Neurology; 2006 Jun; 66(12):1941-3. PubMed ID: 16801668
[TBL] [Abstract][Full Text] [Related]
14. Evidence that folic acid deficiency is a major determinant of hyperhomocysteinemia in Parkinson's disease.
dos Santos EF; Busanello EN; Miglioranza A; Zanatta A; Barchak AG; Vargas CR; Saute J; Rosa C; Carrion MJ; Camargo D; Dalbem A; da Costa JC; de Sousa Miguel SR; de Mello Rieder CR; Wajner M
Metab Brain Dis; 2009 Jun; 24(2):257-69. PubMed ID: 19294496
[TBL] [Abstract][Full Text] [Related]
15. Effects of levodopa and COMT inhibitors on plasma homocysteine in Parkinson's disease patients.
Lamberti P; Zoccolella S; Iliceto G; Armenise E; Fraddosio A; de Mari M; Livrea P
Mov Disord; 2005 Jan; 20(1):69-72. PubMed ID: 15390046
[TBL] [Abstract][Full Text] [Related]
16. Relationship between plasma homocysteine and vitamin status in the Framingham study population. Impact of folic acid fortification.
Selhub J; Jacques PF; Bostom AG; Wilson PW; Rosenberg IH
Public Health Rev; 2000; 28(1-4):117-45. PubMed ID: 11411265
[TBL] [Abstract][Full Text] [Related]
17. Plasma homocysteine levels in patients treated with levodopa: motor and cognitive associations.
Ozer F; Meral H; Hanoglu L; Aydemir T; Yilsen M; Cetin S; Ozturk O; Seval H; Koldas M
Neurol Res; 2006 Dec; 28(8):853-8. PubMed ID: 17288745
[TBL] [Abstract][Full Text] [Related]
18. Modest increase in plasma homocysteine follows levodopa initiation in Parkinson's disease.
O'Suilleabhain PE; Bottiglieri T; Dewey RB; Sharma S; Diaz-Arrastia R
Mov Disord; 2004 Dec; 19(12):1403-8. PubMed ID: 15390053
[TBL] [Abstract][Full Text] [Related]
19. Plasma homocysteine levels in pergolide-treated Parkinson disease patients.
Ozkan S; Colak O; Kutlu C; Ertan M; Alatas O
Clin Neuropharmacol; 2004; 27(4):163-5. PubMed ID: 15319701
[TBL] [Abstract][Full Text] [Related]
20. Role of lifestyle factors on plasma homocysteine levels in Parkison's disease patients treated with levodopa.
Siniscalchi A; Gallelli L; Mercuri NB; Ibbadu GF; De Sarro G
Nutr Neurosci; 2006; 9(1-2):11-6. PubMed ID: 16910165
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]